TCIM
VRTX icon

TIAA CREF Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

TIAA CREF Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$185M Buy
1,005,656
+12,369
+1% +$2.28M 0.13% 159
2018
Q4 		$165M Sell
993,287
-440,752
-31% -$76.4M 0.13% 156
2018
Q3 		$276M Sell
1,434,039
-371,272
-21% -$66.1M 0.18% 121
2018
Q2 		$307M Buy
1,805,311
+189,401
+12% +$29.4M 0.21% 107
2018
Q1 		$263M Sell
1,615,910
-275,572
-15% -$45M 0.18% 121
2017
Q4 		$283M Sell
1,891,482
-267,106
-12% -$39.5M 0.19% 110
2017
Q3 		$328M Buy
2,158,588
+81,285
+4% +$12.2M 0.22% 98
2017
Q2 		$268M Buy
2,077,303
+456,290
+28% +$54.9M 0.19% 114
2017
Q1 		$177M Buy
1,621,013
+321,513
+25% +$28.3M 0.13% 168
2016
Q4 		$95.7M Sell
1,299,500
-102,209
-7% -$8.32M 0.07% 281
2016
Q3 		$122K Sell
1,401,709
-230,372
-14% -$21.8M 0.08% 249
2016
Q2 		$140M Buy
1,632,081
+412,067
+34% +$35.6M 0.11% 201
2016
Q1 		$97M Sell
1,220,014
-371,748
-23% -$33.6M 0.07% 270
2015
Q4 		$200M Buy
1,591,762
+23,099
+1% +$2.79M 0.15% 146
2015
Q3 		$163M Sell
1,568,663
-115,907
-7% -$14.9M 0.13% 165
2015
Q2 		$208M Buy
1,684,570
+478,866
+40% +$60.3M 0.15% 156
2015
Q1 		$142M Buy
1,205,704
+216,514
+22% +$25.9M 0.1% 234
2014
Q4 		$118M Sell
989,190
-60,678
-6% -$6.83M 0.08% 272
2014
Q3 		$118M Sell
1,049,868
-71,668
-6% -$6.82M 0.08% 258
2014
Q2 		$106M Sell
1,121,536
-18,992
-2% -$1.33M 0.07% 290
2014
Q1 		$80.7M Sell
1,140,528
-245,571
-18% -$19.4M 0.06% 353
2013
Q4 		$103M Sell
1,386,099
-424,087
-23% -$29.5M 0.07% 287
2013
Q3 		$137M Sell
1,810,186
-171,066
-9% -$13.6M 0.11% 203
2013
Q2 		$158M Buy
+1,981,252
New +$146M 0.13% 174

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

TIAA CREF Investment Management's VRTX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q1 2019, buying an estimated $2.28M and bringing the position to 1,005,656 shares worth $185M. The position accounts for 0.13% of the portfolio, ranked #159.

TIAA CREF Investment Management first reported a position in VRTX in Q2 2013 and has held it in 24 quarters since. The position peaked at $328M in Q3 2017. 736 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

  • TIAA CREF Investment Management held 1,005,656 shares of Vertex Pharmaceuticals worth $185M as of Q1 2019.
  • TIAA CREF Investment Management bought 12,369 Vertex Pharmaceuticals shares in Q1 2019, an estimated $2.28M.
  • Vertex Pharmaceuticals made up 0.13% of TIAA CREF Investment Management's portfolio in Q1 2019, its #159 holding.
  • TIAA CREF Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Vertex Pharmaceuticals position peaked at $328M in Q3 2017.
  • 736 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.